Carbamazepine and hematological malignancies

References (9)

1. Günaldı M, Paydaş S, Afşar ÇU, Duman BB, Erçolak V, Haksöyler V. Carbamazepine and multiple myeloma: possible interaction. Turk J Hematol 2013;30:83-84
2. Verrotti A, Basciani F Trotta D, Greco R, Morgese G, Chiarelli F Effect of anticonvulsant drugs on interleukins-1, -2 and -6 and monocyte chemoattractant protein-1. Clin Exp Med 2001;1:133-136
3. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 2007;20:625-635
4. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-4256
5. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H; International Myeloma Workshop Consensus Panel 2. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-4700. 6. eHealthMe.com. From FDA Reports: Carbamazepine and Myeloma – Multiple. © 2013. Available at http://www. ehealthme.com/ds/carbamazepine/myeloma+-+multiple
6. Furst SM, Uetrecht JP. The effect of carbamazepine and its reactive metabolite, 9-acridine carboxaldehyde, on immune cell function in vitro. Int J Immunopharmacol 1995;17:445- 452
7. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008;23:27-41
8. Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005;128:7- 17
9. Adelow C, Ahlbom A, Feychting M, Johnsson F Schwartzbaum J, Tomson T. Epilepsy as a risk factor for cancer. J Neurol Neurosurg Psychiatry 2006;77:784-786.